Like Lp-PLA2 inhibitors, NCBV might be a novel therapeutic for Alzheimer’s disease because its supposed mechanism is the inhibition of nerve cell destruction, indicating a protective effect rather than just alleviating the symptoms. The gene discussed is PLA2G7; the disease is early-onset autosomal dominant Alzheimer disease.